Investigating immune responses in heart disease
The role of Immune-responsive gene 1 and itaconate in atherosclerotic disease
This study is looking at how certain genes and a compound called itaconate affect the buildup of plaque in arteries, which can lead to heart problems, with the goal of finding new treatments for people with atherosclerosis.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11051190 on NIH RePORTER |
What this research studies
This research focuses on understanding how immune-responsive gene 1 and itaconate contribute to atherosclerosis, a condition that leads to cardiovascular disease. By examining the inflammatory processes involved in the buildup of plaques in arteries, the research aims to identify specific targets for new therapies. The approach includes studying the role of certain immune pathways and their impact on heart health, which could lead to more effective treatments for patients with atherosclerosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with atherosclerosis or those at high risk for cardiovascular disease due to inflammation.
Not a fit: Patients who do not have atherosclerosis or significant cardiovascular risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that reduce inflammation in atherosclerosis, potentially improving heart health and reducing cardiovascular events.
How similar studies have performed: Previous large-scale clinical trials have shown promise in targeting inflammation for cardiovascular disease, indicating that this approach may lead to meaningful advancements.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Bozal, Fazli Kamer — New York University School of Medicine
- Study coordinator: Bozal, Fazli Kamer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.